Skip to main content
SpringerLink
Log in

Adalimumab/methotrexate/upadacitinib

Pulmonary embolism and deep vein thrombosis: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Choy E, et al. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib select clinical trial program. Annals of the Rheumatic Diseases 79 (Suppl. 1): 317-318 abstr. THU0195, Jun 2020. Available from: URL: https://ard.bmj.com/content/79/Suppl_1/317 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/methotrexate/upadacitinib. Reactions Weekly 1833, 14 (2020). https://doi.org/10.1007/s40278-020-86832-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-86832-x

Search

Navigation